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Activation of executioner caspases is a predictor of
progression-free survival in glioblastoma patients:
a systems medicine approach
A´C Murphy1, B Weyhenmeyer1, J Schmid1, SM Kilbride1, M Rehm1, HJ Huber1, C Senft2,3, J Weissenberger2, V Seifert3, M Dunst4,
M Mittelbronn4, D Ko¨gel2, JHM Prehn1 and BM Murphy*,1
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. GBM cells are highly resistant to
apoptosis induced by antitumor drugs and radiotherapy resulting in cancer progression. We assessed whether a systems
medicine approach, analysing the ability of tumor cells to execute apoptosis could be utilized to predict the response of GBM
patients to treatment. Concentrations of the key proapoptotic proteins procaspase-3, procaspase-9, Smac and Apaf-1 and the
antiapopotic protein XIAP were determined in a panel of GBM cell lines and GBM patient tumor resections. These values were
used as input for APOPTO-CELL, a systems biological based mathematical model built to predict cellular susceptibility to
undergo caspase activation. The modeling was capable of accurately distinguishing between GBM cells that die or survive in
response to treatment with temozolomide in 10 of the 11 lines analysed. Importantly the results obtained using GBM patient
samples show that APOPTO-CELL was capable of stratifying patients according to their progression-free survival times and
predicted the ability of tumor cells to support caspase activation in 16 of the 21 GBM patients analysed. Calculating the
susceptibility to apoptosis execution may be a potent tool in predicting GBM patient therapy responsiveness and may allow for
the use of APOPTO-CELL in a clinical setting.
Cell Death and Disease (2013) 4, e629; doi:10.1038/cddis.2013.157; published online 16 May 2013
Subject Category: Experimental Medicine
Glioblastoma (GBM) is the most common and malignant
primary brain tumor in adults.1,2 The current treatment
regimen for GBM patients of surgical resection, radiotherapy
and temozolomide (TMZ) chemotherapy, can prolong survival
of patients for several months.3,4 However, the median
survival rate for GBM patients remains dismal at B12
months.5
It is widely recognized that one of the major contributors to
the observed resistance of GBMs to chemotherapy and
radiotherapy is the dysregulation of apoptotic pathways.6,7
Indeed, numerous survival proteins have been shown to be
overexpressed in GBM, and attenuated levels of several
proapoptotic proteins have been reported.8,9 However,
systematic analyses examining how such complex alterations
may impact on the ability of GBMs to successfully evade
death signaling pathways have rarely been performed.
The anticancer treatment strategies of chemotherapy and
radiotherapy typically attempt to engage the intrinsic or
mitochondrial pathway of apoptosis to relay their death
signals within their target population.10,11 Briefly, in this
pathway upon mitochondrial outer membrane permeabiliza-
tion (MOMP), cytochrome c is released from the mitochondria
into the cytosol, triggering formation of the apoptosome, which
includes the apoptotic protease activating factor-1 (Apaf-1)
and procaspase-9.12,13 Apoptosome formation enables acti-
vation of the initiator caspase, procaspase-9 and subsequent
activation of the executioner caspases, procaspase-3 and
-7.13–15 Also released from the mitochondria is Smac/
DIABLO, which prevents the X-linked inhibitor of apoptosis
protein (IAPs), XIAP from inhibiting its caspase targets.16,17
Once activated, the executioner caspases cleave key
regulatory and structural proteins to produce most of the
morphological and biochemical changes, characteristic of this
type of cell death.13,15,18,19
As the proteins, Apaf-1, procaspase-9 and procaspase-3,
Smac and XIAP are all critical players in the intrinsic
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mitochondrial pathway of apoptosis, their expression profile
has previously been analysed in GBM cell lines and tumor
samples. Procaspase-9 has been reported to be over-
expressed in brain tumors20 while XIAP overexpression has
been associated with poor prognosis.21 However, few studies
have considered how the interactions of these proteins impact
on the execution of apoptosis within GBMs and more
importantly determined if the ability of a tumor cell to undergo
apoptosis can subsequently be related to patient response to
therapy. Therefore we asked if a systems medicine approach
examining the expression of Apaf-1, procaspase-9 and
procaspase-3, Smac and XIAP could be utilized to determine
GBM patient therapeutic response. We adopted the
previously established mathematical systems model,
APOPTO-CELL22,23 for our study. This model is based on
the biochemical reactions between these critical components
of the intrinsic mitochondrial pathway22 and enabled us to
predict how the interactions between these apoptotic proteins
impacted on apoptosis induction in GBM cell lines and more
importantly GBM patient resections. Our study successfully
demonstrates that a systems medicine approach analysing
the interplay between these five key apoptotic proteins has
clinical applicability and can be utilized to determine the
progression-free survival (PFS) of GBM patients.
Results
Survival rates of individual GBM cell lines differ
following treatment with TMZ. The response of GBM
patients to TMZ can differ significantly.3 To examine this
range of responses we treated our panel of GBM cell lines
with TMZ. Our panel of cell lines consisted of both
commercially available cell lines, A172, U87, U251, U343
and U373 and a cohort of lines derived from patient GBMs,
including both primary (MZ-18, MZ-51, MZ-294, MZ-327) and
recurrent (MZ-256, MZ-304) tumors.24 Cell survival was
analysed using MTT cell viability assays (Figure 1). Following
incubation with 150mM TMZ, a concentration, which has
previously been demonstrated to correspond with the levels
achieved in the serum of patients during treatment,25 one
group of cells had survival rates of 90% or greater even after
an incubation period of 120 h and consisted of MZ-18
(100%), MZ-51 (93%), MZ-256 (100%), MZ-294 (93%),
MZ-304 (100%) and MZ-327 (100%; Figure 1). The second
group of cells, which displayed significantly reduced survival
rates (Po0.01), all o40% after 120 h exposure to TMZ,
consisted of U87 (30%), U251 (10%), U343 (8%), U373
(39%) and A172 (35%; Figure 1). Thus, two distinct groups
of cell lines displaying significantly differing sensitivities to
TMZ were evident. Furthermore, when we treated this
panel of cell lines with the broad-spectrum kinase inhibitor
staurosporine, we also observed a similar pattern of
response and could identify the same two distinct groups of
cells (Supplementary Figure).
GBM cell lines display differential protein expression of
apoptosis-related family members. We next sought to
establish if the expression levels of key proteins in the
mitochondrial apoptotic pathway could be utilized to predict
the observed cellular response to treatment. Accordingly, we
determined the amounts of five apoptosis-related family
members, namely the proapoptotic proteins Apaf-1, procas-
pase-3, procaspase-9 and Smac and the antiapoptotic
protein XIAP in our panel of 11 GBM cell lines using
quantitative western blotting against HeLa cell extracts, in
which concentrations of each protein have previously been
determined (Figure 2a).22 The expression of Apaf-1 and
procaspase-9 were consistently lower in the GBM cell lines
than in the HeLa control (Figures 2b and d). Differential
expression of procaspase-3 was observed in the GBM cell
line lysates with some of the cell lines expressing greater
levels than the HeLa cell line and others expressing lower
levels (Figure 2c). Differential expression of Smac
(Figure 2e) and XIAP (Figure 2f) was also noted in the
GBM cell line lysates with the majority of samples expressing
greater levels of Smac (Figure 2e) and varied levels of XIAP
(Figure 2f) compared with the HeLa control. Statistical
analysis of these protein expression levels relative to
treatment outcome (Figure 1), indicated significantly higher
expression of procaspase-3 in the cell lines that responded to
TMZ, than those which did not respond (Mann–Whitney
U-test; P¼ 0.03). No significant differences were identified in
the expression of Apaf-1 (P¼ 0.93), procaspase-9
(P¼ 0.93), XIAP (P¼ 0.13) and Smac (P¼ 0.25).
A systems medicine approach, analysing apoptosome-
dependent caspase activation based on basal protein
expression levels, predicts the ability of each GBM cell
line to undergo apoptosis. To investigate if the abundance
and the interaction of these apoptotic proteins could be
utilized to calculate cell line response to apoptosis-inducing
therapy we employed APOPTO-CELL, a systems biological
mathematical model developed in our laboratory using HeLa
cells.22 APOPTO-CELL is built on the input of quantitatively
determined procaspase-3, procaspase-9, Smac, Apaf-1 and
XIAP protein levels and its output is the prediction of cellular
susceptibility to undergo caspase cleavage and activation.
The quantities of the apoptosis-related proteins expressed
in each GBM cell line (Table 3A; Supplementary Material)
were used as input for the model system and the time
to achieve 80% substrate cleavage, a level previously
determined to be required for apoptosis to proceed
Figure 1 Treatment with TMZ significantly decreases cell survival in a subset of
GBM cell lines. The panel of GBM cell lines was treated with TMZ (150mM) and a
cell viability assay was carried out at 24, 48, 72, 96 and 120 h post-treatment. Two
groups of cells were evident from this analysis: TMZ tolerant and TMZ sensitive.
Data are expressed as mean±S.E.M. from three independent experiments
(Student’s t-test at end point, **Po0.01)
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efficiently,22 was calculated (Figures 3a and b). The
APOPTO-CELL output, accurately predicted the GBM cell
line sensitivities (Figure 1) in 10 of the 11 cell lines, which
corresponds to a predictive rate of 90.9%. All of the cell lines
we observed as sensitive to TMZ treatment were also
correctly predicted by APOPTO-CELL to achieve appropriate
levels of caspase-3 activation within the 60min simulation
timeframe, with a median time of 26min to achieve 80%
substrate cleavage (Figure 3a). Of the cell lines, which failed
to respond to TMZ in vitro, 83% also failed to reach sufficient
substrate cleavage within the simulation time of 60min
(Figure 3b). The time calculated by APOPTO-CELL to
achieve sufficient levels of caspase-3 activation for efficient
execution of apoptosis varied significantly between the TMZ
sensitive and TMZ tolerant groups of cells (log-rank,
P¼ 0.0007; Figure 3c).
We also undertook an examination of the methylation
status of the promoter region of the DNA-repair enzyme,
Figure 2 GBM cell lines differ in their basal protein expression levels of apoptotic proteins. Untreated whole-cell lysates of GBM cell lines and a HeLa cell line were
analysed by western blotting. Western blots showing basal Apaf-1, procaspase-3, procaspase-9, Smac and XIAP expression levels in 11 GBM cell lines and the HeLa cell line;
b-actin was used as a loading control (a). Densitometry analysis of basal protein expression levels of Apaf-1 (b), procaspase-3; Mann–Whitney U-test, *Po0.05
(c), procaspase-9 (d), Smac (e) and XIAP (f) in tolerant and sensitive GBM cell lines and the HeLa cell line (white bar). Protein expression levels are displayed as a percentage
of HeLa protein expression (100%). Data are expressed as means±S.E.M. from three independent experiments
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O6-methylguanine-DNA methyltransferase (MGMT) in our
cell lines (Table 1), as it has previously been shown that a
methylated MGMT promoter is associated with chemosensi-
tivity to TMZ.26–28 All sensitive cell lines displayedmethylation
of their MGMT promoter, explaining their ability to respond to
TMZ, but so too did 50% of the cell lines, which were
unresponsive to the drug (Table 1), giving an overall predictive
rate of 73% (8 of 11 cell lines). Interestingly, therefore, our
systems medicine approach was better able to explain the
differing responses of the cell lines to TMZ than analysis of the
methylation status of theMGMT promoter (predictive rates of
91 versus 73%, respectively).
Confirming the induction of apoptosis in cell lines
predicted by APOPTO-CELL as TMZ-sensitive. It has
been reported that TMZ predominantly induces an apoptotic
type of cell death in glioma cells.29 To verify that the GBM cell
lines, predicted by APOPTO-CELL as capable of supporting
caspase activation upon appropriate stimulation, were under-
going apoptosis following exposure to TMZ in vitro, two
representative cell lines from the sensitive group, U251 and
U343 and two TMZ-tolerant cell lines, MZ294 and MZ304
were selected for further analysis (Figure 4a). Initially, the
observed cell death following TMZ treatment was quantified
using Hoechst staining (Figure 4b). The loss of viability in the
sensitive cell lines was associated with the appearance of
pyknotic nuclei and morphological changes characteristic of
apoptosis (Figure 4b; *Po0.05). To further examine this
mode of cell death, the cells were treated with TMZ in the
presence and absence of zVAD and stained with AnnexinV
(Figure 4c). Following treatment, TMZ-sensitive cells were
AnnexinV positive in numbers reflective of those achieved by
the previous Hoechst staining of drug-treated cells (Figures
4b and c). The expression of AnnexinV was significantly
(Po0.001) but not entirely blocked by zVAD (Figure 4c). In
correlation with the results obtained from the MTT viability
assay (Figure 1), neither Hoechst nor AnnexinV staining was
evident in the treated MZ294 and MZ304 cells (Figures 4b
and c). Apoptotic death of the sensitive lines following TMZ
treatment was also supported by the activation of the
executioner caspase-3, and cleavage of the caspase
substrate PARP in the sensitive cell lines, but not in the
TMZ-tolerant lines (Figure 4d). Collectively these data
Figure 3 The APOPTO-CELL outputs for TMZ tolerant and sensitive GBM cell
lines. The calculated protein expression levels of procaspase-3, Apaf-1,
procaspase-9, Smac and XIAP in the 11 GBM cell lines were used as input for
the APOPTO-CELL model software. The time (min) taken to achieve 80%
caspase-3 substrate cleavage after cytochrome c release was calculated for
the TMZ tolerant (a) and TMZ sensitive GBM cell lines (b). Kaplan–Meier
curve showing that the predicted times to 80% caspase-3 substrate cleavage
vary significantly between TMZ tolerant and sensitive cell lines ((c); log-rank
P¼ 0.0007)
Table 1 Cell line characteristics
Cell line Response to TMZ Methylation status
of MGMT promoter
p53 status
U87 Sensitive Methylated Wild-type42
U251 Sensitive Methylated Mutant42
U343 Sensitive Methylated Mutant43
U373 Sensitive Methylated Mutant42
A172 Sensitive Methylated Wild-type42
MZ-18 Tolerant Methylated Unknown
MZ-51 Tolerant Methylated Unknown
MZ-256 Tolerant Unmethylated Unknown
MZ-294 Tolerant Methylated Unknown
MZ-304 Tolerant Unmethylated Unknown
MZ-327 Tolerant Unmethylated Unknown
Abbreviation: TMZ, temozolomide.
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(Figures 4b–d) provide strong support for the role of the
intrinsic apoptotic pathway as a critical mediator of cell death
elicited by TMZ within the sensitive GBM cell lines. Although
not a focus of this study, other forms of cell death may also
make a contribution, however.
Application of the systems model, APOPTO-CELL
determines PFS of GBM patients. Having identified the
potential use of a systems biology approach to predict the
response of GBM cell lines to treatment, we hypothesized
that this approach could be applied in a clinical setting to
predict patient responses to therapy. Therefore, we analysed
tumor resections isolated from 21 GBM patients by quanti-
tative western blotting,22 to determine the levels of the
proapoptotic proteins Apaf-1, procaspase-3, procaspase-9
and Smac and the antiapoptotic protein XIAP (Figure 5). The
expression of Apaf-1 was comparable to the HeLa control
(Figure 5a). Examination of the data showed significantly
greater expression of procaspase-3 in certain GBM patient
samples compared with others and when compared with the
Figure 4 U251 and U343 cells undergo caspase-dependent apoptosis following treatment with TMZ. APOPTO-CELL outputs for two TMZ-tolerant cell lines, MZ294 and
MZ304, and two TMZ-sensitive cell lines, U251 and U343 (a). All cell lines were treated with TMZ (150mM) for 72 h. TMZ-induced apoptosis was assessed by Hoechst and
AnnexinV positive staining and western blot analysis. Brightfield and UV-light images ( 20 magnification) of TMZ-treated GBM cells following Hoechst staining (b),
condensed/fragmented nuclei were considered apoptotic, counted and expressed as a percentage of the total cell number ((b); *Po0.05, n¼ 3). The cell lines were treated
with TMZ in the presence or absence of zVAD for 72 h and TMZ-induced apoptosis was determined by AnnexinV positive staining using flow cytometry ((c); ***Po0.001;
versus control treated cells, þ þ þPo0.001; versus TMZ-treated cells). Data are expressed as mean±S.E.M. from three independent experiments. Western blot analysis of
the protein expression levels of procaspase-3, cleaved caspase-3, PARP and cleaved PARP in the cell lines following TMZ treatment for 72 h (d)
Systems biology to predict GBM patient survival
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HeLa standard (Figure 5b). In contrast and consistent
with the findings in cell lines, levels of procaspase-9 in all
GBM resections were consistently lower than the HeLa
standard control (Figure 5c). Differential expression of
Smac and XIAP was observed in the patient samples with the
majority of samples expressing greater levels of Smac
(Figure 5d) but lower levels of XIAP expression compared
with the HeLa control (Figure 5e). A statistical analysis of
these protein expression levels relative to patient PFS
times (Table 2), indicated significantly higher expression
of procaspase-3 in the patients with longer PFS times
(47 months) than in those individuals with shorter PFS times
(o7 months; Mann–Whitney U-test; P¼ 0.004). No signi-
ficant differences were identified in the expression of
Apaf-1 (P¼ 0.59), procaspase-9 (P¼ 0.34), XIAP (P¼ 0.86)
and Smac (P¼ 0.051).
Next, using the calculated concentrations of the apoptosis-
related family of proteins as input (Table 3B; Supplementary
Material), the APOPTO-CELL model was used to determine
the susceptibility towards caspase activation for each patient.
Figure 6a shows the APOPTO-CELL predictions for those
patients surviving 7 months or longer without tumor reoccur-
rence and all were predicted to be capable of supporting
executioner caspase activation (Figure 6a). Of the eight
patients who had suffered tumor reoccurrence within
7 months, three were also accurately predicted by
APOPTO-CELL as being incapable of activating sufficient
levels of executioner caspases (Figure 6b). Analysis of the
data showed that the predicted time to achieve 80% substrate
cleavagewas significantly shorter for patients with longer PFS
times than for those patients whose tumors had reoccurred
within the same timeframe (6.3min versus 24.6min, log-rank
test, P¼ 0.0047; Figure 6c). Overall, the APOPTO-CELL
model had a predicative rate of 76.2% as the model’s
substrate cleavage profiles correlated with PFS times in 16
of the 21 patients analysed.
We also undertook an analysis of the methylation status
of the MGMT promoter within the patient tumor samples
(Table 2). Amongst the patients with short PFS times
(o7 months), six had unmethylated promoters and the
remaining two had inconclusive results despite repeated
analysis. For patients with longer PFS times (47 months),
five expressed a methylated promoter and five expressed an
unmethylated promoter. Three samples were again incon-
clusive. Regarding patients with short PFS times, the MGMT
promoter methylation analysis had a greater predictive rate
(100% (6/6) versus 37.5% (3/8)), while for those patients with
longer PFS times, the APOPTO-CELL model was more
accurate (40% (4/10) versus 100% (13/13)), indicating
perhaps that when apoptosis can occur in a system, the
APOPTO-CELL model is better able to predict overall
outcome. Taking both patient populations into consideration
and excluding those with unknown status of their MGMT
promoter, the APOPTO-CELL model was more accurate as a
predictive determinant of patient PFS times (62.5% (10/16)
versus 81.25% (13/16)). However, given the limited number
of patient-derived samples and the retrospective analysis
of clinical data that were accessible for this study, this
result will need to be validated independently and in a larger
clinical cohort.
Figure 5 Determination of apoptosis-associated protein concentrations in
resections from GBM patients. The patient samples were grouped according to their
PFS times. Those with PFS times of 4 7 months were defined as long-term
while those with PFS times of o 7 months were defined as short-term. The
concentrations of Apaf-1 (a), procaspase-3; Mann–Whitney U-test, *Po0.05 (b),
procaspase-9 (c), Smac (d) and XIAP (e) were determined in resections from
GBM patients by western blotting and densitometry. These concentrations were
compared with a HeLa standard control (white bar), data expressed as mean
±SEM for 3 independent experiments
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Discussion
This study highlights the potential use of a systems medicine
approach in determining PFS in GBM patients. We
have validated our previous systems biology approach,22,23
and demonstrated that determining the interaction between
apoptosis-associated proteins, namely Apaf-1, procaspase-3,
procaspase-9, Smac and XIAP, can predict the susceptibility
of GBM cell lines to undergo apoptosis following treatment
with TMZ. Importantly, analysis of the simulated interplay
between quantitatively determined expression levels of these
proteins in resected tumor patient samples allowed for the
retrospective stratification of GBM patients with long or short-
term PFS times, 47 months and o7months, respectively,
thus delivering a unique and novel prognostic tool.
This study collectively assessed the basal levels of Apaf-1,
procaspase-3, procaspase-9, Smac and XIAP in GBM patient
samples and a panel of human cell lines. Establishing the
basal levels of these apoptotic proteins within GBMs is
essential as it determines if these tumor cells have the
molecular machinery necessary to undergo apoptosis follow-
ing MOMP. After the release of cytochrome c from the
mitochondria, it binds Apaf-1 resulting in the recruitment of
procaspase-9 and formation of the apoptosome.13 We have
shown that all patient samples and GBM cell lines express
these proteins and therefore, in theory, have the ability to
undergo apoptosis following MOMP. However, we observed
low-levels of procaspase-9 in GBM patient samples and
low-levels of procaspase-9 and Apaf-1 in the GBM cell lines,
when compared with the HeLa control. It has previously been
published that HeLa cell lines express levels of procaspase-9
that are similar to other cancer cell lines and its levels of Apaf-
1 are lower than other cancer cell lines.22 In contrast to our
data, procaspase-9 has previously been shown to be over-
expressed in brain tumors.20 There is conflicting evidence in
the literature as to whether Apaf-1 is upregulated in GBM30 or
downregulated.31 Our finding of low-procaspase-9 expression
in GBM patient samples and both low procaspase-9 and
Apaf-1 expression in GBM cell lines may account, in part, for
the observed apoptosis resistance in GBM as it could result
in reduced apoptosome formation after the release of
cytochrome c.
Elucidating the basal expression levels of these proteins in
GBM allowed us to examine the validity of using these
proteins individually as discriminators of patient or cell line
response to treatment. XIAP, a member of the IAPs, is known
to inhibit apoptosis by binding to caspase-9 and downstream
effector caspases 3 and 7.32 Previous studies have shown
XIAP to be primarily highly expressed in GBM cell lines and its
overexpression associated with poor prognosis.21 This study
demonstrated predominantly low-levels of XIAP expression in
patient samples and varied expression levels in the GBM cell
lines and these basal levels did not correlate with the PFS
times of GBM patients, nor with the susceptibility of GBM cell
lines to undergo apoptosis. Similarly, basal levels of procas-
pase-9, Apaf-1 or Smac were unable to discriminate between
patients with short or long PFS times or GBM cell lines that
were sensitive or tolerant to treatment with TMZ. Interestingly,
Table 2 Patient clinical characteristics
Patient
number
Tumor
entity
Age Sex KPS Treatment
strategy before
resection
Steroid
use
Dose reduction PFS (months) Methylation
status of
MGMT promoter
1 GBM 48 F 100 None No No 17.2 Unmethylated
2 GBM 59 F 90 None No No 16.8 Unknown
3 GBM 22 F 100 None No No Ltf after 46.5 Unmethylated
4 GBM 42 F 90 None No No 21.5 Methylated
5 GBM 68 M 30 None No Unknown Ltf after 10 Unmethylated
6 GBM 66 M 80 None Yes No 11.1 Unknown
7 GBM 71 F 70 None No No 16.1 Unmethylated
8 GBM,
recurrence
70 F 80 None No Unknown Ltf after 10 Methylated
9 GBM 59 F 80 None No Yes
(thrombocytopenia)
8.4 Unknown
11 GBM 59 M 70 None No No 7.4 Unmethylated
12 GBM 61 M 70 None No No 2.6 Unmethylated
13 GBM 44 M 90 None No No 6.1 Unmethylated
14 GBM 55 F 70 None No No 5.4 Unknown
16 GBM 67 M 70 None Yes No 3.7 Unmethylated
17 GBM 64 F 60 None Yes No 8.9 Methylated
18 GBM,
recurrence
53 F 70 Combined radiotherapy
and TMZ-therapy before
resection
No Yes (pancytopenia) 6.9 Unmethylated
19 GBM,
recurrence
66 M 80 Combined radiotherapy
and TMZ-therapy before
resection
No No 2.7 Unmethylated
20 GBM 66 M 90 None No No 7.3 Unmethylated
21 GBM 55 F 90 None No No 3.3 Unknown
22 GBM 53 F 60 None No No 7.5 Methylated
23 GBM,
recurrence
55 F 90 Combined radiotherapy
and TMZ-therapy before
resection
Yes No 2.3 Unmethylated
Abbreviations: GBM, glioblastoma, MGMT, O6-methylguanine-DNA methyltransferase; PFS, progression-free survival; KPS, karnofsky performance score; Ltf, lost
to follow up.
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differential expression of procaspase-3 was observed in the
GBM patient samples and in the GBM cell lines, and was
found to correlate with TMZ sensitivity in the cell lines and PFS
times in patients. High-expression levels of active caspase-3
have been previously shown to be associated with an
apoptotic phenotype of cells in GBM patient samples,33 and
therefore our data suggest that longer PFS times in patients
may be associated with a higher rate of apoptosis within the
tumors. Of note, three patients were exposed to chemo-
radiation before surgery, and it cannot be excluded that this
may have resulted in the altered expression levels of the
apoptotic proteins examined for these individuals. In future,
more comprehensive studies are required to investigate this
caveat further.
However, the use of a statistical test as a method of
stratifying patients into those likely to respond best to
apoptosis-inducing therapies requires a large cohort of patient
data to be statistically meaningful and, most crucially, is less
able to predict how patients may respond to new therapeutics
that interfere with this signaling pathway. Our systems biology
approach, APOPTO-CELL, overcomes this obstacle by
analyzing the dynamic interactions of five key apoptotic
proteins in an individual patient sample. This method may
become highly relevant in the clinical setting, as it may allow
for a redefinition of clinical phenotypes, and a stratification of
patients who may respond and may not respond to radio/
chemotherapy, or who may benefit from novel chemother-
apeutics such as Smac mimetics/IAP antagonists. TMZ is the
current standard chemotherapeutic drug for GBM patients.3,4
To date, the only significant predictive marker of GBM patient
response to TMZ is the DNA repair enzyme MGMT. Patients
with MGMT promoter methylation have a much better
prognosis with TMZ than those without it.27,28 We too
observed that the tumors isolated from our patient cohort
with short PFS times all expressed unmethylated MGMT
promoters. However, due to the lack of alternative therapeutic
strategies for patients and the fact that even patients without
MGMT promoter methylation can respond to treatment with
TMZ,26 as was also highlighted by our methylation analysis of
MGMT promoter amongst the patient cohort with longer PFS
times, this biomarker analysis has no direct influence on
treatment strategy options for the clinician. Regardless of
MGMT promoter methylation status, the prognosis for GBM
remains dismal, with the median survival rate for patients with
these highly aggressive brain tumors being 12 months.4,34 As
a result, new treatment paradigms are continually being
explored. Targeting IAPs to release caspases and stimulate
apoptosis is being investigated for various cancers, with some
IAP-targeting drugs currently in preclinical trials.35 Interest-
ingly, targeting XIAP through gene transfer of Smac or
exposure to Smac peptides has been shown to sensitize
GBM cells in vitro and in vivo to apoptosis induced by tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL)36
Figure 6 APOPTO-CELL outputs of resections from GBM patients. Concentra-
tions of Apaf-1, procaspase-3, procaspase-9, Smac, and XIAP in GBM patient
resections were entered into the APOPTO-CELL software. The time to 80%
substrate cleavage following cytochrome c release was calculated for each sample.
APOPTO-CELL outputs for long-term progression-free survivors (a) and for short-
term progression-free survivors (b). Kaplan–Meier curve showing that the predicted
times to 80% caspase-3 substrate cleavage are significantly shorter for patients with
long-term PFS times compared with patients with short-term PFS times ((c); median
6.3 min versus 24.6 min, log-rank test, P¼ 0.0047)
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and by g-irradiation.37 In GBM, where a decrease in apopto-
some components may contribute to drug resistance, it may
also prove beneficial to trial agents that increase the expression
of apoptosome components Apaf-1 and procaspase-9, for
example, by utilizing the pan-histone deacetylase inhibitor
LAQ824.38 Thus, APOPTO-CELL may be a useful tool for
classifying patients who will benefit from these novel therapies
that target the intrinsic apoptotic pathway andmay in the future
help oncologists make better informed treatment decisions.
In conclusion, few if any studies have examined the
combination of these apoptosis-associated proteins or indeed
taken into consideration their possible interactions, when
investigating potential treatment outcomes. Consequently,
our analysis incorporating the interactions amongst these
proteins represents a novel strategy for predicting patient
outcome in GBM. Considering the wealth of strategies
targeting apoptosis in GBM currently in clinical trials,39,40 this
systems medicine approach for determining GBM therapeutic
response not only has validity for today’s patients but also will
be highly valuable in the future treatment of GBM.
Materials and Methods
GBM cell lines. The commercially available GBM cell lines A172, U87, U251,
U343 and U373, as well as the established GBM cell lines MZ-18, MZ-51, MZ-294,
MZ-304, MZ-327 and MZ256 were kindly donated by Prof Donat Ko¨gel of Johann
Wolfgang Goethe University Hospital, Frankfurt, Germany. The characterization of
the commercially available cell lines is available from the American Type Culture
Collection and the newly established cell lines have previously been characterized
by immunostaining.24 The cells were grown in DMEM with 10% heat-inactivated
fetal calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin and were
maintained in a humidified incubator at 37 1C and 5% CO2. HeLa cells were grown
and maintained under the same conditions.
MTT assay. The GBM cell lines were plated in 96-well plates (500–2000 cells/
well), treated with TMZ (150mM) and a cell viability assay was carried out 24, 48, 72,
96 and 120 h post-treatment. Following treatment, thiazolyl blue tetrazolium bromide
(MTT, 5 mg/ml; Sigma Aldrich, Dublin, Ireland) was added to each well and
incubated in the dark at 37 1C. MTT produces a yellowish solution that is converted
to dark blue, water-insoluble MTT formazan by mitochondrial dehydrogenases of
living cells. After 4 h, the medium was aspirated and the dark blue crystals were
dissolved in DMSO (200ml). The absorbance of each sample was measured at
560 nm using a microplate reader (GENios, Tecan, Mannedorf, Switzerland). The
absorbance was considered proportional to the number of viable cells.
Patient samples. Patient samples were obtained from the tumor tissue bank at
the University Cancer Centre, Frankfurt (Table 2). Their use was approved by the
local ethics committee of the Frankfurt University Hospital. These resections were
removed from patients before treatment with radiotherapy and TMZ chemotherapy
except for patients 18, 19 and 23. PFS time is defined as the period of time between
surgical removal of the tumor and subsequent tumor regrowth. For classification
purposes, any patient who had a PFS time of greater than 7 months was classified a
long-term progression-free survivor and any patient who had a PFS time of less than
7 months was classified a short-term progression-free survivor. This stratification
enabled an optimum number of patients (n) in each group (long-term PFS, n¼ 13;
short term PFS, n¼ 8; Table 2) for meaningful statistical analysis.
MGMT promoter methylation status assessed by methylation-
specific PCR (MSP). Tumor specimens showing the largest amount of vital
tumor tissue (goal:470% vital tumor tissue) were selected for MSP. Four slides
of 10-mm thickness were cut from each paraffin block. Slides were deparaffinized
using xylene and 2 96% alcohol. DNA-Isolation was performed using DNeasy
Blood & Tissue Kit (Qiagen, Hilden, Germany). DNA was isolated from the cell
lines using QIAamp DNA Mini Kit (Qiagen). Nucleic acid concentration was
determined by UV spectrophotometric analysis using Nanodrop 1000
Spectrophotometer.
DNA was treated with sodium bisulfite using the EZ DNA Methylation-Gold Kit
(Zymo Research, ORT, New York, NY, USA). PCR run was performed on the
Thermocycler T3000 (Biometra, Gottingen, Germany). For PCR, 2 ml of sodium
bisulfite-pretreated DNA was amplified by the following primer sets:
(I) MGMT-methylated forward primer: 50-GTTTTTAGAACGTTTTGCGTTT
CGAC-30; (II) MGMT-methylated reverse primer: 50-CACCGTCCCGAAAAAAAACT
CCG-30;
(III) MGMT-unmethylated forward primer: 50-TGTGTTTTTAGAATGTTTTGTGTT
TTGAT-30;
(IV) MGMT-unmethylated reverse primer: 50-CTACCACCATCCCAAAAAAAAAC
TCCA-30. DNA from the glioma cell line LNT229 was used as positive control for a
methylated MGMT promoter and DNA from healthy volunteer donors were used as
positive control for an unmethylated MGMT promoter status. Water was used as
negative control in each MSP run. After MSP, 20 ml of each sample was loaded on a
2% agarose-gel at 120 V for 35 min.
Hoechst staining of nuclear chromatin. Hoechst staining was
performed on both untreated control cells and cells treated with TMZ (150mM)
for 72 h. Cells were stained with Hoechst 33258 (1 mg/ml; Sigma Aldrich),
incubated for 10 min at 37 1C and nuclear morphology was visualized using an
Eclipse TE 300 inverted microscope (Nikon, Du¨sseldorf, Germany) using a 20
objective. A minimum of 300 cells were counted in three subfields of each culture.
Those cells with condensed/fragmented nuclei were deemed apoptotic, counted
(using ImageJ software, National Institute of Mental Health, Bethesda, MD, USA)
and expressed as a percentage of total cell number.
Western blot analysis. Resected tumor tissue from GBM patients and GBM
cell lines were homogenized in lysis buffer containing 0.5 mmol/l Tris-HCl (pH 6.8),
2% SDS (w/v), 10% glycerin (w/v) and protease and phosphatase inhibitor
cocktails (Sigma Aldrich). After determining the protein concentration of the
samples using a BCA protein assay (Pierce, Rockford, IL, USA), 20mg samples
were boiled in gel-loading buffer and separated on 10–15% SDS-PAGE gels.
Proteins were transferred to nitrocellulose membranes using the iBlot gel transfer
device (Life Technologies, Invitrogen, Paisley, Scotland). The membranes were
incubated with the following antibodies: Smac, caspase-3, caspase-9 (Cell
signalling Technology, Beverly, MA, USA), XIAP (BD Biosciences, Oxford, UK)
and Apaf-1 (Chemicon, Hampshire, UK). For the GBM cell lines treated with TMZ
(150mM) for 72 h, the membranes were incubated with antibodies against
caspase-3, cleaved caspase-3, PARP and cleaved PARP (Cell signalling
Technology). Membranes were next incubated with horseradish peroxidase-
conjugated secondary antibodies (Jackson ImmunoResearch, Plymouth, PA,
USA) and protein bands were visualized using Supersignal West Pico
Chemiluminescent Substrate (Pierce). Images were captured using a LAS-3000
Imager equipped with a cooled 12 bit digital CCD camera (FUJIFILM UK Ltd
Systems, Sheffield, UK).
For quantitative western blotting, standard curves from HeLa cell extracts
(5–20 mg) were run concurrently with the GBM cell line and patient lysates (20 mg) to
ensure linearity of the signal detection range. The protein concentrations of Apaf-1,
procaspase-9, procaspase-3, Smac and XIAP within each GBM cell line and
individual GBM patient resected tumor sample were determined by comparison to
signals from HeLa cell extracts (Table 3; Supplementary Material). The
concentrations of each protein in HeLa cells were previously determined and
adapted from Rehm et al.,22 Special care was taken not to overexpose any pixels to
guarantee accurate quantifications. Digital densitometry was performed using
ImageJ software after background subtraction by quantifying signal intensities of the
chemiluminescence signals and normalized to b actin. For all proteins at least
three detections were evaluated. Data are expressed as mean±S.E.M.
Flow cytometry. MZ-294, MZ304, U251 and U343 cell were pretreated with
zVAD (50mM) for 30 min and then treated with TMZ (150 mM) for 72 h. Following
treatment, monolayer cells were harvested with trypsin-EDTA and washed with
PBS. Cells were then incubated at room temperature in binding buffer (10 mM
HEPES, 135 mM NaCl, 5 mM CaCl2), which contained an AnnexinV-FITC conjugate
(1 ml/ml; BioVision, Mountain View, CA, USA) for 15 min. Cells were counted in a
BD LSR II flow cytometer (BD Biosciences). Excitation of AnnexinV-FITC was
done with a 488 nm laser and fluorescence emission was collected in the FL1
channel through a 520 nm band pass filter. A total of 1  104 gated cells were
acquired for each sample and analysed using the Flowmax software (Partec,
Munster, Germany).
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Mathematical modeling of apoptosis execution. The model used is
the biochemical reactions network, APOPTO-CELL, previously published.22,23 This
model is based on a set of ordinary differential equations representing a reaction
network of 53 reactions, 19 reaction partners and 75 reaction parameters and is
implemented in MATLAB. The model was developed in HeLa cells and validated in
cellulo and by adapting the model to cancer cell lines deficient in apoptosis
signaling proteins.22,41 The reaction network is initiated by cytochrome
c-dependent apoptosome formation and mitochondrial Smac release while
substrate cleavage by effector caspases is the model output.23 To generate
substrate cleavage profiles for the GBM cell lines and GBM patient samples,
protein expression values for procaspases-9 and -3, XIAP, Smac and Apaf-1, as
determined by quantitative western blotting for each individual patient sample and
cell line, were used as input for APOPTO-CELL and modeled over 60 min.
At 60 min varied substrate cleavage profiles were predicted, ranging from o1 to
100%. Apoptosis susceptibility in GBM tumor resections and GBM cell lines was
defined as the ability to efficiently generate480% substrate cleavage within this
60 min timeframe. A 480% substrate cleavage was chosen as it has previously
been determined that this % enables apoptosis to proceed efficiently.22
Statistical analysis. Student’s t-test was used to analyse the response to
TMZ in the cell lines. Mann–Whitney U-tests were performed to identify significant
differences in protein expression relative to b-actin between TMZ sensitive and
resistant cell lines and between GBM patient long- and short-term PFS times. To
compare the censored times to sufficient caspase activation predicted by systems
modeling between TMZ sensitive and resistant cell lines after apoptosis inducing
treatment and between patients having long- and short-term PFS, we used log-
rank tests on the Kaplan–Meier plots. A P-value of o0.05 was considered to be
statistically significant.
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